Tactogen

Why it matters: TACT908 (2ZEDMA) is a benzofuran-based serotonin receptor agonist (5-HT1B/5-HT2A) designed for cluster headache without producing hallucinations. Cluster headache patients often report sub-hallucinogenic doses of psychedelics abort attacks — TACT908 is designed to replicate this mechanism without the psychedelic experience, enabling non-supervised use.

Watch next: IND-enabling data and Phase 1 FIH timeline announcement

Likely: Q3 2026

No public source found confirming completed regulatory acceptance for MDMA+citalopram in August 2024. Public sources support a paused/planned programme under strategic review after Lykos FDA rejection.

Why it matters: The Lykos rejection created regulatory uncertainty for all MDMA-based PTSD therapies. Tactogen's MDMA+citalopram combination (where citalopram attenuates the subjective MDMA "high") was positioned to address the FDA's therapy-component criticism, but the broader regulatory climate post-Lykos makes any MDMA PTSD programme more challenging.

Watch next: Tactogen announcement or registry entry confirming MDMA+citalopram IND clearance, Phase 2 launch, or formal deprioritisation.

Why it matters: Tactogen's benzofuran entactogens are structurally derived from 5-MAPB (a widely studied MDMA-like benzofuran) but with optimised selectivity to reduce neurotoxicity, cardiovascular risk, and abuse potential. Preliminary Phase 1 data comparing 5-MAPB to MDMA showed equivalent reductions in social anxiety and improvements in self-compassion, validating the benzofuran pharmacology.

Watch next: Lead compound selection from TACT833/411/523 series and IND-enabling timeline